Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435277 | 0.84 | F10 (0.43) | F10PDE4BTLR2TLR1MDM2 | |
| SCHEMBL5435274 | 0.84 | F10 (0.43) | F10PDE4BTLR2TLR1MDM2 | |
| SCHEMBL5443667 | 0.83 | PDE4B (0.43) | F10PDE4BTLR2TLR1MDM2 | |
| SCHEMBL14428332 | 0.80 | KMT2A (0.44) | F10TLR2TLR1MDM2BACE1 | |
| SCHEMBL14490681 | 0.79 | KMT2A (0.39) | F10KMT2AEPHX2 | |
| SCHEMBL20479997 | 0.79 | PDE4B (0.45) | PDE4BKMT2AUSP30 | |
| SCHEMBL20479996 | 0.79 | PDE4B (0.45) | PDE4BKMT2AUSP30 | |
| SCHEMBL20479950 | 0.79 | PDE4B (0.45) | PDE4BKMT2AUSP30 | |
| SCHEMBL20479951 | 0.79 | PDE4B (0.45) | PDE4BKMT2AUSP30 | |
| SCHEMBL20479995 | 0.79 | PDE4B (0.45) | PDE4BKMT2AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | F10 53/4885PDE4B 796/4885TLR2 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.